Medicine moves
our lives.
What happens if we do nothing.
If research and innovation lose their appeal, there will be direct consequences for Switzerland. Companies will invest less and expertise will migrate abroad.
This affects not only the economy but also medical care. Without innovation, there is less progress in the long term – and thus fewer innovative and new therapies for patients.
The strength of Switzerland as a pharmaceutical hub is closely linked to our healthcare provision.
Medicine moves our lives – faster than ever before. Stay up to date with the latest information.
A strong future for Switzerland requires rapid access to innovations for patients as well as stable, internationally competitive framework conditions for research and production. A reliable environment and a modern pricing system that enables and sustainably secures innovation are crucial for this.
Ensuring access to innovation
Switzerland is currently losing ground – decisive action is now needed to ensure patient access to innovations.
It is now essential to work together with policymakers toward a solution that creates the best possible framework conditions to guarantee the Swiss population long-term access to innovative and life-saving medicines.
Attractive framework conditions for research and production
Research and production require stable, reliable, and internationally competitive framework conditions.
The starting position for the pharmaceutical industry in Switzerland has changed fundamentally. Pharmaceutical companies must increasingly invest heavily in research and production in large markets such as the USA and China to secure access to these key markets. As a result, competition between locations in the rest of the world is becoming increasingly fierce. This puts Switzerland’s position as a pharmaceutical hub under pressure.
More clinical research, well-trained specialists, access to international sales markets, and constructive cooperation between all relevant stakeholders are needed once again to secure and further develop the research and production location.
Modernized pricing system
Pricing must enable innovation, not prevent it.
Pricing must enable innovation, not prevent it.
The pricing and reimbursement process for new medicinal products in Switzerland is increasingly reaching its limits. Despite a legal requirement of 60 days, the process until reimbursement takes an average of over 180 days. This delay impairs timely access to innovative therapies, reduces the quality of care in the healthcare system, and weakens the attractiveness of Switzerland as a location for research and business.
The right course must be set now.
Without innovation-friendly framework conditions, Switzerland will lose both access to investment and future prospects.